文献速递结核与非结核分枝杆菌

结核性脑膜炎成人患者利福平血浆与脑脊液群体药代动力学

Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.
PubMed 文献 · J Infect Dis · 2025-01-01

该随机对照试验纳入48名HIV相关结核性脑膜炎成人,比较标准剂量(口服10 mg/kg)与高剂量利福平(口服35 mg/kg或静脉20 mg/kg)的血浆及脑脊液药代动力学。采用非线性混合效应模型分析400份血浆和44份脑脊液样本,发现标准剂量利福平脑脊液穿透率约6%,模拟显示标准剂量未能在脑脊液中达到结核分枝杆菌临界浓度。

要点

  • 标准剂量利福平脑脊液穿透率约6%, equilibration半衰期为3.2小时。
  • 标准剂量模拟未能在脑脊液达到结核分枝杆菌临界浓度以上。
  • 高剂量利福平药代动力学参数被成功表征,支持继续评估其用于结核性脑膜炎治疗。

核心结论

  • 标准剂量利福平的脑脊液穿透率低,模拟显示未能在脑脊液达到结核分枝杆菌临界浓度以上。
  • 研究结果支持继续评估高剂量利福平用于结核性脑膜炎治疗。

研究设计与样本

  • 随机对照试验,纳入48名HIV相关结核性脑膜炎成人,随机分配至高剂量利福平实验组(口服35 mg/kg或静脉20 mg/kg)联合利奈唑胺±阿司匹林,或标准治疗对照组(口服利福平10 mg/kg)。
  • 使用400份血浆和44份脑脊液利福平浓度数据,通过非线性混合效应模型分析。

主要发现

  • 中位(范围)年龄39岁(25-78),体重60 kg(30-107)。
  • 标准剂量第3天和第28天典型清除率分别为33.1 L/h和41.4 L/h;高剂量分别为46.1 L/h和70.2 L/h。
  • 脑脊液-血浆比值约为6%,平衡半衰期为3.2小时。
  • 模拟标准剂量利福平未能在脑脊液达到结核分枝杆菌临界浓度以上。

临床怎么用

  • 标准剂量利福平脑脊液穿透有限,模拟未达结核分枝杆菌临界浓度。
  • 研究支持继续评估高剂量利福平用于结核性脑膜炎治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several ongoing clinical trials are evaluating high-dose rifampicin (up to 35 mg/kg) for tuberculous meningitis (TBM). However, rifampicin pharmacokinetics at higher doses is not fully characterized, particularly in cerebrospinal fluid (CSF), the site of TBM disease. METHODS: In a randomized controlled trial, adults with HIV-associated TBM were assigned to experimental arms of high-dose rifampicin (oral, 35 mg/kg; intravenous, 20 mg/kg) plus linezolid, with or without aspirin, or a control arm that received the standard of care with 10 mg/kg of oral rifampicin. Rifampicin concentrations, including the unbound fraction, were measured on plasma samples, and CSF was collected on days 3 and 28 of study enrollment. Data were analyzed by nonlinear mixed effects modeling. RESULTS: In total, 400 plasma and 44 CSF rifampicin concentrations from 48 participants were used for model development. The median (range) age and weight were 39 years (25-78) and 60 kg (30-107). Rifampicin pharmacokinetics was best described by a 2-compartment disposition model with first-order transit oral absorption and elimination via saturable hepatic extraction. Typical clearance values for the standard dose for days 3 and 28 were 33.1 and 41.4 L/h, respectively; high-dose values were 46.1 and 70.2 L/h. The CSF-plasma ratio was approximately 6% and the equilibration half-life was 3.2 hours. Simulated standard-dose rifampicin did not reach CSF concentrations above the critical concentration for Mycobacterium tuberculosis. CONCLUSIONS: CSF penetration with standard-dose rifampicin is low. Our findings support continued evaluation of high-dose rifampicin for TBM treatment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Abdelgawad N, Wasserman S, Gausi K, et al. Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis. J Infect Dis. 2025. PMID: 40295169. doi:10.1093/infdis/jiaf178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。